News

Bigbank AS Secures Success with Unsecured Bond Offering

Bigbank AS Secures Success with Unsecured Bond Offering

Bigbank AS Achieves Milestone with Unsecured Bond Offering

The public offering of Bigbank AS (Bigbank) unsecured subordinated bonds, known as the Offering, has concluded recently. This initiative marked the third series under Bigbank's unsecured subordinated bond programme, allowing the bank to raise a total of up to 30 million euros.

Details of the Offering

Bigbank offered up to 3,000 unsecured subordinated bonds, each carrying a nominal value of EUR 1,000. These bonds are set to mature on 23 October 2034, featuring a fixed interest rate of 6.5% per annum, with payments made quarterly. Remarkably, in light of investor demand, Bigbank retained the option to increase the offering volume by an additional 5,000 bonds, potentially raising the total to 8,000 bonds. Notably, this Offering was conducted across Estonia, Latvia, and Lithuania.

Investor Participation and Allocation

A total of 789 investors engaged in the subscription process, placing orders for the subordinated bonds that collectively amounted to 8.7 million euros. This remarkable interest indicated that the base issue volume of 3 million euros was oversubscribed by nearly three times. Consequently, Bigbank decided to exercise its right to expand the Offering, ultimately setting the total volume at 5 million euros.

Allocation Principles for Investors

The Management Board of Bigbank laid out clear principles for bond allocation:

  • All subscription orders from the same subscriber were aggregated.
  • Subscriptions from investors up to 30,000 euros were fully accepted.
  • Employees from companies within the Bigbank group were allocated 100% of their subscribed amount.
  • Investors were granted 2.75% of their subscription exceeding 30,000 euros.
  • The number of bonds allocated was rounded to the nearest whole number where applicable.

Statements from the Management

In a statement, Martin Länts, Chairman of the Management Board at Bigbank, expressed gratitude towards all participating investors for their trust in the bank's growth strategy. He noted, "The subscription results underscore the unwavering confidence of investors in Bigbank's future and its strategic direction. However, the offered interest rate might have been perceived as a tad high due to recent fluctuations in the interest rate environment. The capital acquired will substantially bolster Bigbank's capacity to implement its business strategy, primarily focusing on expansion in the housing and corporate loan sectors, while adhering to regulatory capital requirements."

Upcoming Trading Expectations

Investors can anticipate that the bonds will be transferred to their respective securities accounts around 23 October. The first trading day for these bonds on the Baltic Bonds List of Nasdaq Tallinn Stock Exchange is expected to commence on or about 24 October.

About Bigbank AS

Bigbank AS, established over 30 years ago, is a commercial bank with Estonian ownership. As of the latest reports, the bank's total assets were valued at 2.6 billion euros, with an equity amounting to 252.8 million euros. The bank operates in nine countries, catering to more than 150,000 active customers and employing over 500 personnel. Moody's, the credit rating agency, has assigned Bigbank a Ba1 long-term deposit rating along with a baseline credit assessment (BCA) and an adjusted BCA of Ba2.

For more information, you can reach Argo Kiltsmann, a member of the Management Board, via phone at +372 53 930 833 or email at Argo.Kiltsmann@bigbank.ee. For additional details, visit www.bigbank.ee.

Frequently Asked Questions

What is the total amount Bigbank AS aimed to raise?

Bigbank AS aimed to raise up to 30 million euros through its bond offering.

How many investors participated in the Offering?

A total of 789 investors participated in the subscription for the subordinated bonds.

What was the nominal value of each bond in the Offering?

Each bond offered had a nominal value of EUR 1,000.

What was the interest rate for the subordinated bonds?

The bonds carried a fixed interest rate of 6.5% per annum, payable quarterly.

When can investors expect to trade the bonds?

Investors can expect the bonds to start trading on or around 24 October.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Copper Peptides Shine in New Renue Blue Cream

Updated Category News Views 171

Renue By Science's Ambitious Skincare Launch Alright, we've got a big player stepping up in the realm of skincare with a new face cream packed tightly with science-backed goodies. Renue By Science is revamping their game by anchoring their new Renue Blue Face Cream around the star of the moment: copper tripeptide-1, also known as GHK-Cu. This is more than a beauty gloss...

Continue Reading
Alley Cat Allies Pushes for Humane Cat Conservation Bill

Updated Category News Views 70

Time to Rethink Conservation: Save the Cats If you’re tuned into the chatter buzzing around the Cayman Islands, you know the clocks are ticking for a decision that could change the approach to handling community cats. Alley Cat Allies is waving the flag, urging the Cayman Islands Parliament to pass a bill that abandons the archaic practice of culling cats by shooting...

Continue Reading
Cognito Unveils Phase 3 Results for Alzheimer Treatment

Updated Category News Views 292

Charting New Waters in Alzheimer's Treatment Well, here's one for the books, folks. Cognito Therapeutics just tossed their latest Phase 3 results from their so-called HOPE study into the ring. We're talking about Spectris AD, a non-drug, at-home gizmo that aims to be the next big thing for Alzheimer's. Yeah, the study didn't exactly hit a home run with the primary...

Continue Reading
Endava's Audit Scandal: Investors Face Crucial Decision

Updated Category News Views 156

Endava's Unexpected Crisis: What's Happening? It's the kind of mess no investor wants to wake up to: on October 28, 2026, Endava plc (NYSE: DAVA) laid out a smorgasbord of screw-ups that have left the market reeling. The company's last few days were a whirlwind, featuring the CFO's abrupt exit and the CEO swap. This shake-up didn't happen in isolation—the announcement...

Continue Reading
Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 136

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
Kos & FORTH Partner to Spark Greek Biotech Growth

Updated Category News Views 81

New Frontiers: Greece on the Biotech Map Partnerships in biotech aren't tossed out willy-nilly; they're crafted for precision much like a sculptor shaping marble. Kos Biotechnology Partners and the Foundation for Research and Technology-Hellas (FORTH) are doing exactly that, teaming up to birth a biotechnology incubator on the FORTH campus in Heraklion, Crete. Now tell...

Continue Reading
Local Bounti Expands: Acquires CEA Facilities

Updated Category News Views 72

Local Bounti's Strategic Acquisition Move Local Bounti's at it again, shaking up the indoor agriculture scene by snapping up some real estate from Revol Greens. We're talking 30 acres of primo certified-organic greenhouse space across Texas and Minnesota. And they’re picking these babies up right as they’re ready to grow, not like some flashy land grab. Digging into...

Continue Reading
Quantum X and Everest Cloud Partner in South Asia Push

Updated Category News Views 108

An Unlikely Alliance for Cutting-Edge Tech You gotta admit, the fusion of a U.S.-based tech outfit with a Nepalese cloud provider wasn't the market move anyone saw coming. But here we are—Quantum X is hitching its quantum computing dreams to Everest Cloud's solid local foothold across six South Asian markets. We're talking Nepal, India, Bangladesh, Bhutan, Sri Lanka,...

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 118

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading
Apotex Enters U.S. Market with Axitinib Tablets Launch

Updated Category News Views 114

Apotex's Bold Move: Axitinib Tablets Hit the U.S. Market Apotex is shaking things up in the pharma world by launching the first generic version of Axitinib Tablets in the U.S., aimed at treating advanced renal cell carcinoma (RCC) when previous treatments have fallen flat. This isn't just another dance with the red tape—it's a major step for Apotex, flexing their muscle...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Natural Hydrogen: MAX Power Mining's Vision

Updated Category News Views 184

MAX Power Mining Corp. Driving Innovation in Natural Hydrogen In an era where energy demands are escalating, especially with the rise of artificial intelligence and advanced technologies, the search for sustainable power sources has reached new heights. Enter MAX Power Mining Corp. (OTC: MAXXF) (CSE: MAXX), a trailblazer in the natural hydrogen sector, demonstrating...

Continue Reading
Inland Empire Health Plan Achieves Excellence in GIS Recognition

Updated Category News Views 246

A Celebration of Achievement for Inland Empire Health Plan Inland Empire Health Plan (IEHP) has achieved remarkable recognition by winning its third Special Achievement in GIS (SAG) award from Esri, the global leader in Geographic Information System (GIS) technology. This prestigious accolade highlights IEHP's commitment to utilizing innovative technology to enhance...

Continue Reading
Ryp Labs Triumphs in Lineage’s Global Food Innovation Challenge

Updated Category News Views 226

Ryp Labs Triumphs in Lineage’s Global Food Innovation Challenge In a groundbreaking moment for sustainable food technology, Ryp Labs was announced as the standout winner of Lineage's prestigious innovation challenge aimed at transforming the global food supply chain. The challenge focused on innovative solutions that address pressing issues such as food waste and supply...

Continue Reading
Future Landscape of the UV Stabilizers Market by 2032

Updated Category News Views 176

Growth of the UV Stabilizers Market The UV stabilizers market is gaining momentum, projected to expand from USD 1.4 billion to USD 2.3 billion by 2032, with a compound annual growth rate (CAGR) of 5.5% during the 2024-2032 period. This growth is fueled by the increasing demand for materials that are durable and can endure the degrading effects of ultraviolet (UV)...

Continue Reading
Dr. Rushika Fernandopulle Joins Premera Board of Directors

Updated Category News Views 337

Dr. Rushika Fernandopulle Joins Premera's Board Premera Blue Cross is excited to announce the addition of Dr. Rushika Fernandopulle to its Board of Directors. This decision is part of a strategic effort to strengthen leadership and expertise within the organization. Dr. Fernandopulle takes over from Dr. John Jenrette, who has completed his term this year. Expertise and...

Continue Reading